Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2006-10-10
2006-10-10
Bernhardt, Emily (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
C544S130000, C544S238000, C544S295000, C544S357000, C544S360000, C544S336000, C544S366000, C544S367000, C544S369000, C544S374000, C544S383000, C544S408000, C546S187000, C546S193000, C546S194000, C546S207000, C546S210000, C546S212000, C546S214000, C546S233000, C514S235500, C514S252020, C514S252030, C514S252110, C514S252180, C514S253090, C514S253120, C514S253110, C514S254100, C514S254050, C514S255020, C514S255050, C514S254030, C514S314000, C514S316000, C514S318000, C514S323000, C514S326000, C514S327000, C514S
Reexamination Certificate
active
07119203
ABSTRACT:
This invention is directed generally to proteinase (also known as “protease”) inhibitors, and, more particularly, to piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. Such hydroxamic acids generally correspond in structure to the following formula:(wherein A1, A2, Y, E1, E2, E3, and Rxare as defined in this specification), and further include salts of such compounds. This invention also is directed to compositions of such hydroxamic acids, intermediates for the syntheses of such hydroxamic acids, methods for making such hydroxamic acids, and methods for treating conditions (particularly pathological conditions) associated with MMP activity and/or aggrecanase activity.
REFERENCES:
patent: 4595700 (1986-06-01), Donald et al.
patent: 5451676 (1995-09-01), Whittaker et al.
patent: 5472978 (1995-12-01), Baker et al.
patent: 5475138 (1995-12-01), Pal et al.
patent: 5599994 (1997-02-01), Pal et al.
patent: 5932595 (1999-08-01), Bender et al.
patent: 5998412 (1999-12-01), Broka et al.
patent: 6013649 (2000-01-01), Freskos et al.
patent: 6300514 (2001-10-01), Takahashi et al.
patent: 6372758 (2002-04-01), DeCrescenzo et al.
patent: 6448250 (2002-09-01), DeCrescenzo et al.
patent: 6492367 (2002-12-01), DeCrescenzo et al.
patent: 6495568 (2002-12-01), Dack et al.
patent: 6683078 (2004-01-01), Barta et al.
patent: 6683093 (2004-01-01), Barta et al.
patent: 6689794 (2004-02-01), Freskos et al.
patent: 6800646 (2004-10-01), DeCrescenzo et al.
patent: 2003/0073718 (2003-04-01), Barta et al.
patent: 2003/0171404 (2003-09-01), Barta et al.
patent: 0 266 182 (1988-05-01), None
patent: 0 336 354 (1989-10-01), None
patent: 0 606 046 (1994-07-01), None
patent: 0 780 386 (1997-06-01), None
patent: 0 930 067 (1999-07-01), None
patent: 0 931 788 (1999-07-01), None
patent: 1081137 (2001-03-01), None
patent: 1067965 (1967-05-01), None
patent: 2263109 (1993-07-01), None
patent: 4-338331 (1992-11-01), None
patent: WO 90/05719 (1990-05-01), None
patent: WO 93/20047 (1993-10-01), None
patent: WO 94/02466 (1994-02-01), None
patent: WO 94/24140 (1994-10-01), None
patent: WO 95/04720 (1995-02-01), None
patent: WO 95/09841 (1995-04-01), None
patent: WO 95/13064 (1995-05-01), None
patent: WO 95/13289 (1995-05-01), None
patent: WO 95/29892 (1995-11-01), None
patent: WO 96/06074 (1996-02-01), None
patent: WO 96/11209 (1996-04-01), None
patent: WO 97/05865 (1997-02-01), None
patent: WO 97/20824 (1997-06-01), None
patent: WO 97/24117 (1997-07-01), None
patent: WO 97/48368 (1997-12-01), None
patent: WO 98/37877 (1998-09-01), None
patent: WO 98/38163 (1998-09-01), None
patent: WO 98/38859 (1998-09-01), None
patent: WO 98/39329 (1998-09-01), None
patent: WO 99/09000 (1999-02-01), None
patent: WO 99/24399 (1999-05-01), None
patent: WO 99/25687 (1999-05-01), None
patent: WO 99/29667 (1999-06-01), None
patent: WO 99/42436 (1999-08-01), None
patent: WO 00/38717 (2000-06-01), None
patent: WO 00/46221 (2000-08-01), None
patent: WO 00/50396 (2000-08-01), None
patent: WO 00/59874 (2000-10-01), None
patent: WO 00/69819 (2000-11-01), None
patent: WO 00/69821 (2000-11-01), None
patent: WO 00/74681 (2000-12-01), None
patent: WO 02/092588 (2002-11-01), None
patent: WO 03/007930 (2003-01-01), None
Boehm et al. U.S. Appl. No. 10/877,450, filed Jul. 8, 2004.
McDonald et al. U.S. Appl. No. 10/700,202, filed Nov. 3, 2003.
Barta et al. U.S. Appl. No. 09/311,837, filed May 14, 1999.
Freskos et al. U.S. Appl. No. 10/142,737, filed May 10, 2002.
Freskos et al. U.S. Appl. No. 10/291,983, filed Nov. 12, 2002.
DeCrescenzo et al. U.S. Appl. No. 10/262,622, filed Sep. 30, 2002.
Brown, “Synthetic Inhibitors of Matrix Metalloproteinases”;Matrix Metalloproteinases, pp. 243-261 (Academic Press, San Diego, CA, Eds. Park, W.C., & Mecham, R.P., 1998).
Dack, et al., “Preparation of N-hydroxytetrahydropyridylsulfonylacetamides and related compounds as matrix metalloprotease inhibitors,” CA 131:44740 (1999) [CA Plus Accession No. 1999:388166].
Denis, et al., “Matrix metalloproteinase inhibitors: Present achievements and future prospects,”Invest New Drugs, 15:175-185 (1997).
Freije, et al., “Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas,”J. Biol. Chem., 269(24), pp. 16766-16773 (1994).
Gearing, et al., “Processing of tumour necrosis factor-α precursor by metalloproteinases,”Nature, 370:555-557 (1994).
Gu, et al., “S-Nitrosylation of Matrix Metalloproteinases: Signaling Pathway to Neuronal Cell Death,”Science, 297, 1186-1190 (2002).
Hughes, et al., “Monoclonal antibodies that specifically recognize neoepitope sequences generated by ‘aggrecanase’ and matrix metalloproteinase cleavage of aggrecan: application to catabolismin situandin vitro,” Biochem. J., 305, 799-804 (1995).
Kenyon, et al., “A model of angiogenesis in the mouse cornea,”Invest Ophthalmol. Vis. Sci., 37(8):1625-1632 (1996).
Knight, et al., “A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases,”FEBS Lett., 296(3):263-266 (1992).
Kuzmic, et al., “High-throughput screening of enzyme inhibitor: simultaneous determination of tright-binding inhibition constants and enzyme concentration,”Anal. Biochem., 286, 45-50 (2000).
Luckow, et al., “Insect Cell Expression Technology”,Protein Enginerring: Principles and Practice, pp. 183-218 (John Wiley & Sons, Inc., New York, NY, Edited by J.L. Cleland et al., 1996).
Luckow, et al., “Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated inEscherihia coli,” J. Virol., 67(8):4566-4579 (1993).
McClure, et al., “Matrix metalloprotease (MMP)-13 selective inhibitors for treatment of arthritis deformans and other MMP-related diseases,” CA 131:125454 (1999) [CA Plus Accession No. 1999:468334].
McGeehan, et al., “Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor,”Nature, 370:558-561 (1994).
Mitchell, et al., “Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage,”J. Clin. Invest., 97(3):761-768 (1996).
Rasmussen, et al., “Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat,”Pharmacol. Ther., 75(1):69-75 (1997).
Reboul, et al., “The new collagenase, collagnease-3, is expressed and synthesized by human chondrocytes but not by synoviocytes,”J. Clin. Invest., 97(9):2011-2019 (1996).
Schwartz, et al., “Synthetic inhibitors of bacterial and mammalian interstitial collagenases,”Prog. In Med. Chem., 29:271-334 (1992).
Tang, “ADAMTS: a novel family of extracellular matrix proteases,”Int'l J. Biochem. Cell Biol., 33, 33-44 (2001).
Woessner, “The Matrix Metalloproteinase Family,”Matrix Metalloproteinases, pp. 1-14 (Academic Press, San Diego, CA, Eds. Parks, W.C. & Mecham, R.P., 1998).
A partial search report from PCT Appl. No. PCT/US03/13123.
Oct. 9, 2003 Search Report and Aug. 3, 2004 International Preliminary Examination Report from International Patent Application No. PCT/US03/13123.
Barta Thomas E.
Becker Daniel P.
Bedell Louis J.
Boehm Terri L.
Brown David L.
Bernhardt Emily
Pharmacia Corporation
Pharmacia Corporation
LandOfFree
Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3677655